MedTrace Logo

Vaccine Therapy in Treating Patients With Stage IIB, Stage III, or Stage IV Colorectal Cancer

NCT00091286 · Status: TERMINATED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2020-03-30

No results posted yet for this study

Summary

RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells.

PURPOSE: This clinical trial is studying how well vaccine therapy works in treating patients with stage IIB, stage III, or stage IV colorectal cancer.

Conditions

Interventions

BIOLOGICAL

HER-2-neu, CEA peptides, GM-CSF, Montanide ISA-51 vaccine

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Craig L Slingluff, Jr

    lead OTHER

Principal Investigators

  • Charles M. Friel, MD · University of Virginia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-03-24
Primary Completion
2008-02-15
Completion
2008-02-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00091286 on ClinicalTrials.gov